Modality
Radioligand
MOA
AHRant
Target
BCMA
Pathway
RNA Splicing
MG
Development Pipeline
Preclinical
~May 2015
→ ~Aug 2016
Phase 1
~Nov 2016
→ ~Feb 2018
Phase 2
May 2018
→ Oct 2029
Phase 2Current
NCT03462396
2,650 pts·MG
2018-05→2029-10·Not yet recruiting
NCT03005057
2,144 pts·MG
2021-11→2027-11·Active
4,794 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-11-251.7y awayPh3 Readout· MG
2029-10-023.5y awayPh3 Readout· MG
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P2/3
Not yet…
P2/3
Active
Catalysts
Ph3 Readout
2027-11-25 · 1.7y away
MG
Ph3 Readout
2029-10-02 · 3.5y away
MG
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03462396 | Phase 2/3 | MG | Not yet recr... | 2650 | CfB |
| NCT03005057 | Phase 2/3 | MG | Active | 2144 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| BII-5449 | Biogen | Phase 3 | FXIa | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA |